| Product Code: ETC8271998 | Publication Date: Sep 2024 | Updated Date: Aug 2025 | Product Type: Market Research Report | |
| Publisher: 6Wresearch | Author: Sumit Sagar | No. of Pages: 75 | No. of Figures: 35 | No. of Tables: 20 |
1 Executive Summary |
2 Introduction |
2.1 Key Highlights of the Report |
2.2 Report Description |
2.3 Market Scope & Segmentation |
2.4 Research Methodology |
2.5 Assumptions |
3 Mexico Alpha-1 Antitrypsin Deficiency (AATD) Augmentation Therapy Market Overview |
3.1 Mexico Country Macro Economic Indicators |
3.2 Mexico Alpha-1 Antitrypsin Deficiency (AATD) Augmentation Therapy Market Revenues & Volume, 2021 & 2031F |
3.3 Mexico Alpha-1 Antitrypsin Deficiency (AATD) Augmentation Therapy Market - Industry Life Cycle |
3.4 Mexico Alpha-1 Antitrypsin Deficiency (AATD) Augmentation Therapy Market - Porter's Five Forces |
3.5 Mexico Alpha-1 Antitrypsin Deficiency (AATD) Augmentation Therapy Market Revenues & Volume Share, By Drugs, 2021 & 2031F |
3.6 Mexico Alpha-1 Antitrypsin Deficiency (AATD) Augmentation Therapy Market Revenues & Volume Share, By Gene Type, 2021 & 2031F |
3.7 Mexico Alpha-1 Antitrypsin Deficiency (AATD) Augmentation Therapy Market Revenues & Volume Share, By Application, 2021 & 2031F |
3.8 Mexico Alpha-1 Antitrypsin Deficiency (AATD) Augmentation Therapy Market Revenues & Volume Share, By End User, 2021 & 2031F |
3.9 Mexico Alpha-1 Antitrypsin Deficiency (AATD) Augmentation Therapy Market Revenues & Volume Share, By Distribution Channel, 2021 & 2031F |
4 Mexico Alpha-1 Antitrypsin Deficiency (AATD) Augmentation Therapy Market Dynamics |
4.1 Impact Analysis |
4.2 Market Drivers |
4.2.1 Increasing awareness about alpha-1 antitrypsin deficiency (AATD) among healthcare professionals and patients |
4.2.2 Growing prevalence of AATD in Mexico leading to higher demand for augmentation therapy |
4.2.3 Technological advancements in the development of AATD augmentation therapies |
4.3 Market Restraints |
4.3.1 High cost associated with AATD augmentation therapy |
4.3.2 Limited reimbursement policies for AATD treatments in Mexico |
4.3.3 Challenges in diagnosis and identification of AATD patients leading to underdiagnosis |
5 Mexico Alpha-1 Antitrypsin Deficiency (AATD) Augmentation Therapy Market Trends |
6 Mexico Alpha-1 Antitrypsin Deficiency (AATD) Augmentation Therapy Market, By Types |
6.1 Mexico Alpha-1 Antitrypsin Deficiency (AATD) Augmentation Therapy Market, By Drugs |
6.1.1 Overview and Analysis |
6.1.2 Mexico Alpha-1 Antitrypsin Deficiency (AATD) Augmentation Therapy Market Revenues & Volume, By Drugs, 2021- 2031F |
6.1.3 Mexico Alpha-1 Antitrypsin Deficiency (AATD) Augmentation Therapy Market Revenues & Volume, By Prolastin, 2021- 2031F |
6.1.4 Mexico Alpha-1 Antitrypsin Deficiency (AATD) Augmentation Therapy Market Revenues & Volume, By Zemaira/Respreeza, 2021- 2031F |
6.1.5 Mexico Alpha-1 Antitrypsin Deficiency (AATD) Augmentation Therapy Market Revenues & Volume, By Glassia, 2021- 2031F |
6.1.6 Mexico Alpha-1 Antitrypsin Deficiency (AATD) Augmentation Therapy Market Revenues & Volume, By Aralast NP, 2021- 2031F |
6.1.7 Mexico Alpha-1 Antitrypsin Deficiency (AATD) Augmentation Therapy Market Revenues & Volume, By Others, 2021- 2031F |
6.2 Mexico Alpha-1 Antitrypsin Deficiency (AATD) Augmentation Therapy Market, By Gene Type |
6.2.1 Overview and Analysis |
6.2.2 Mexico Alpha-1 Antitrypsin Deficiency (AATD) Augmentation Therapy Market Revenues & Volume, By Type PiZZ, 2021- 2031F |
6.2.3 Mexico Alpha-1 Antitrypsin Deficiency (AATD) Augmentation Therapy Market Revenues & Volume, By Type PiMS, 2021- 2031F |
6.2.4 Mexico Alpha-1 Antitrypsin Deficiency (AATD) Augmentation Therapy Market Revenues & Volume, By Type PiMZ, 2021- 2031F |
6.2.5 Mexico Alpha-1 Antitrypsin Deficiency (AATD) Augmentation Therapy Market Revenues & Volume, By Others, 2021- 2031F |
6.3 Mexico Alpha-1 Antitrypsin Deficiency (AATD) Augmentation Therapy Market, By Application |
6.3.1 Overview and Analysis |
6.3.2 Mexico Alpha-1 Antitrypsin Deficiency (AATD) Augmentation Therapy Market Revenues & Volume, By Lung Disease, 2021- 2031F |
6.3.3 Mexico Alpha-1 Antitrypsin Deficiency (AATD) Augmentation Therapy Market Revenues & Volume, By Liver Disease, 2021- 2031F |
6.3.4 Mexico Alpha-1 Antitrypsin Deficiency (AATD) Augmentation Therapy Market Revenues & Volume, By Population Type, 2021- 2031F |
6.3.5 Mexico Alpha-1 Antitrypsin Deficiency (AATD) Augmentation Therapy Market Revenues & Volume, By Adults and Pediatric, 2021- 2031F |
6.4 Mexico Alpha-1 Antitrypsin Deficiency (AATD) Augmentation Therapy Market, By End User |
6.4.1 Overview and Analysis |
6.4.2 Mexico Alpha-1 Antitrypsin Deficiency (AATD) Augmentation Therapy Market Revenues & Volume, By Hospitals, 2021- 2031F |
6.4.3 Mexico Alpha-1 Antitrypsin Deficiency (AATD) Augmentation Therapy Market Revenues & Volume, By Specialty Clinics, 2021- 2031F |
6.4.4 Mexico Alpha-1 Antitrypsin Deficiency (AATD) Augmentation Therapy Market Revenues & Volume, By Home Healthcare, 2021- 2031F |
6.4.5 Mexico Alpha-1 Antitrypsin Deficiency (AATD) Augmentation Therapy Market Revenues & Volume, By Others, 2021- 2031F |
6.5 Mexico Alpha-1 Antitrypsin Deficiency (AATD) Augmentation Therapy Market, By Distribution Channel |
6.5.1 Overview and Analysis |
6.5.2 Mexico Alpha-1 Antitrypsin Deficiency (AATD) Augmentation Therapy Market Revenues & Volume, By Hospital Pharmacy, 2021- 2031F |
6.5.3 Mexico Alpha-1 Antitrypsin Deficiency (AATD) Augmentation Therapy Market Revenues & Volume, By Retail Pharmacy, 2021- 2031F |
6.5.4 Mexico Alpha-1 Antitrypsin Deficiency (AATD) Augmentation Therapy Market Revenues & Volume, By Online Pharmacy, 2021- 2031F |
6.5.5 Mexico Alpha-1 Antitrypsin Deficiency (AATD) Augmentation Therapy Market Revenues & Volume, By Others, 2021- 2031F |
7 Mexico Alpha-1 Antitrypsin Deficiency (AATD) Augmentation Therapy Market Import-Export Trade Statistics |
7.1 Mexico Alpha-1 Antitrypsin Deficiency (AATD) Augmentation Therapy Market Export to Major Countries |
7.2 Mexico Alpha-1 Antitrypsin Deficiency (AATD) Augmentation Therapy Market Imports from Major Countries |
8 Mexico Alpha-1 Antitrypsin Deficiency (AATD) Augmentation Therapy Market Key Performance Indicators |
8.1 Number of healthcare professionals trained in diagnosing and treating AATD |
8.2 Percentage increase in AATD patients receiving augmentation therapy |
8.3 Average time taken for AATD diagnosis from initial presentation |
8.4 Adoption rate of new AATD augmentation therapies |
8.5 Patient adherence rate to AATD augmentation therapy |
9 Mexico Alpha-1 Antitrypsin Deficiency (AATD) Augmentation Therapy Market - Opportunity Assessment |
9.1 Mexico Alpha-1 Antitrypsin Deficiency (AATD) Augmentation Therapy Market Opportunity Assessment, By Drugs, 2021 & 2031F |
9.2 Mexico Alpha-1 Antitrypsin Deficiency (AATD) Augmentation Therapy Market Opportunity Assessment, By Gene Type, 2021 & 2031F |
9.3 Mexico Alpha-1 Antitrypsin Deficiency (AATD) Augmentation Therapy Market Opportunity Assessment, By Application, 2021 & 2031F |
9.4 Mexico Alpha-1 Antitrypsin Deficiency (AATD) Augmentation Therapy Market Opportunity Assessment, By End User, 2021 & 2031F |
9.5 Mexico Alpha-1 Antitrypsin Deficiency (AATD) Augmentation Therapy Market Opportunity Assessment, By Distribution Channel, 2021 & 2031F |
10 Mexico Alpha-1 Antitrypsin Deficiency (AATD) Augmentation Therapy Market - Competitive Landscape |
10.1 Mexico Alpha-1 Antitrypsin Deficiency (AATD) Augmentation Therapy Market Revenue Share, By Companies, 2024 |
10.2 Mexico Alpha-1 Antitrypsin Deficiency (AATD) Augmentation Therapy Market Competitive Benchmarking, By Operating and Technical Parameters |
11 Company Profiles |
12 Recommendations |
13 Disclaimer |
Export potential enables firms to identify high-growth global markets with greater confidence by combining advanced trade intelligence with a structured quantitative methodology. The framework analyzes emerging demand trends and country-level import patterns while integrating macroeconomic and trade datasets such as GDP and population forecasts, bilateral import–export flows, tariff structures, elasticity differentials between developed and developing economies, geographic distance, and import demand projections. Using weighted trade values from 2020–2024 as the base period to project country-to-country export potential for 2030, these inputs are operationalized through calculated drivers such as gravity model parameters, tariff impact factors, and projected GDP per-capita growth. Through an analysis of hidden potentials, demand hotspots, and market conditions that are most favorable to success, this method enables firms to focus on target countries, maximize returns, and global expansion with data, backed by accuracy.
By factoring in the projected importer demand gap that is currently unmet and could be potential opportunity, it identifies the potential for the Exporter (Country) among 190 countries, against the general trade analysis, which identifies the biggest importer or exporter.
To discover high-growth global markets and optimize your business strategy:
Click Here